Cardiovascular Disease

Drawing of two arteries in the heart with arrows showing direction of blood flow
Cardiovascular Disease Management

Increasing efficiencies with breakthrough technologies

Cardiovascular disease is the leading cause of death for both men and women worldwide, with billions of dollars spent globally on its diagnosis, management and treatment.1,2 By 2030, the global cost of cardiovascular diseases will be more than $1 trillion (USD), with nearly one-third of all deaths caused by cardiovascular diseases.2 An estimated 17.5 million people worldwide die each year from cardiovascular diseases.3

Our vision is to transform the treatment of cardiovascular disease by creating cost-effective technologies that save and improve lives. 


OPTIS™ integrated system

PCI Optimization Portfolio

Combine the power of fractional flow reserve (FFR)—the gold standard for lesion assessment—with the accuracy and precise insight of optical coherence tomography (OCT) to identify and treat coronary lesions.

Related Portfolio

Discover additional cost-effective technologies designed to save and improve the lives of patients with cardiovascular disease.

Embolization Portfolio

Advance your standard of care for peripheral embolization through single device occlusion with minimally invasive, implantable vascular plugs uniquely designed for specific situations.

Know What to Treat and How to Treat

Optimize percutaneous coronary intervention (PCI) with the power of fractional flow reserve (FFR) and the accuracy of optical coherence tomography (OCT) technologies. Our systems give you precisely the information you need, where and when you need it—for more informed decision-making, greater efficiency and improved procedural effectiveness, especially in patients with complex lesions.

The technology is so advanced that it makes it very easy for the operator to get the information and very easy to interpret it.
—Dr. Augusto D. Pichard

Watch this video to see what physicians say about fractional flow reserve (FFR) and optical coherence tomography (OCT).

Only Abbott offers a portfolio that combines both FFR and OCT technologies to optimize treatment decisions. Learn more about our PCI Optimization portfolio.

Health care professional reviewing clinical evidence on a computer and clipboard with data

Clinical Evidence 

At Abbott, we are committed to advancing the practice of medicine—providing clinical evidence, better tools and groundbreaking technologies to guide treatment decisions. Our portfolio of products for PCI optimization is backed by a solid body of clinical evidence.

See evidence for PCI optimization.


The color gold is a trademark of St. Jude Medical, Inc. and its related companies
1. Centers for Disease Control and Prevention. Heart disease facts. Retrieved from
2. Bloom, D. E., Cafiero, E. T., Jané-Llopis, E., Abrahams-Gessel, S., Bloom, L. R., Fathima, S., ... Weinstein, C. (2011). The global economic burden of noncommunicable diseases. Presented at the meeting of the World Economic Forum. Geneva, Switzerland.
3. World Health Organization. Global status report on noncommunicable diseases 2014. (2014). Geneva, Switzerland. Retrieved from

Orange 24 surrounded by headset, represents "Place an order"

Contact Customer Service

Our customer service experts can help with your product orders or questions.